Noticias y vídeos - ESSA PHARMA INC.

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference PR Newswire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 SOUTH SAN FRANCISCO , Calif. and VANCOUVER, BC , April 9, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Bloom Burton & Co....

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS PR Newswire SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 SOUTH SAN FRANCISCO , USA and VANCOUVER, CANADA , March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. (" ESSA " or the " Company ") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2024 Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA...

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 6, 2024 SOUTH SAN FRANCISCO , California and VANCOUVER, Canada , Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual...

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Jan. 25, 2024 Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 81%...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023 PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 12, 2023 Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023 Head-to-head Phase 2 dose expansion underway evaluating...

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 21, 2023 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35 th...

ESSA Pharma to Present at the Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 SOUTH SAN FRANCISCO , Calif. and VANCOUVER, Canada , Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on...

ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 6, 2023 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales...

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 26, 2023 Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently enrolled into cohort four, 81% of patients achieved PSA90, 69% of patients achieved...

Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma? PR Newswire NEW YORK, Oct. 25, 2023 NEW YORK , Oct. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BITF, INVO, LCID, ESMT, and EPIX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BITF:...

Thinking about buying stock in Bitfarms, Invo Bioscience, Lucid Group, EngageSmart, or ESSA Pharma? PR Newswire NEW YORK, Oct. 24, 2023 NEW YORK , Oct. 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BITF, INVO, LCID, ESMT, and EPIX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BITF:...

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress PR Newswire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Oct. 21, 2023 Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently enrolled into cohort four, 69% of patients achieved PSA90, 63% of patients achieved PSA90 in...

Thinking about buying stock in Lithium Americas, AGNC Investment, PCTEL, ESSA Pharma, or Sigma Additive Solutions? PR Newswire NEW YORK, Oct. 16, 2023 NEW YORK , Oct. 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAC, AGNC, PCTI, EPIX, and SASI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. LAC:...

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Sept. 18, 2023 Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase 1 results selected for a poster presentation...

ESSA Pharma Insiders Establish Automatic Securities Disposition Plans PR Newswire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Aug. 31, 2023 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Aug. 31, 2023 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that each of its President and Chief Executive Officer, David R Parkinson and its...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 PR Newswire SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 8, 2023 Completion of the Phase 1 EPI-7386 combination study with Xtandi ® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Entered into clinical trial support agreement with Janssen to supply Erleada ® (apalutamide) and Zytiga ®...

ESSA Pharma Appoints Lauren Merendino to its Board of Directors PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 SOUTH SAN FRANCISCO , California and VANCOUVER, Canada , June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino , M.B.A., to its Board of Directors. Ms....

ESSA Pharma to Present at 2023 Jefferies Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on...

ESSA Pharma to Present at JMP Securities Life Sciences Conference PR Newswire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , May 11, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences...